Every 10-Q that Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SHPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SHPH filings page.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported a net loss of $5,298,010 and no revenue for the six months ended June 30, 2026, compared with a $6,759,472 net loss and no revenue in the 2025 period. Cash and cash equivalents were $90,238 at June 30, 2026; operating activities used $2,984,949 in cash during the six months.
In May 2026, Shuttle completed its merger with United Dogecoin, but said it had not obtained control as of June 30 because stockholder approval remained outstanding and contractual restrictions limited its authority over United Dogecoin’s operations. Its recorded investment in United Dogecoin was $13,683,474, including $3,897,500 of PIPE proceeds invested to support operations.
Shuttle reported substantial doubt about its ability to continue as a going concern within one year after the statements are issued. Cash and equity-offering proceeds are not expected to fund operations through the next 12 months. Management plans a near-term capital raise targeting between $120 million and $150 million and is in the final stages of negotiating a data center land deal; completion of the financing cannot be guaranteed.
Shuttle Pharmaceuticals Holdings, Inc. reported a net loss of about $2.2 million for the three months ended March 31, 2026, with no revenue and a working capital deficit of approximately $5.8 million. Cash and cash equivalents were $1.09 million, leaving the company dependent on external financing.
In March 2026 Shuttle raised gross proceeds of $3.5 million through an underwritten offering of 2,238,800 common shares and 4,761,200 pre-funded warrants. Management states that existing resources, recent equity raises and a revolving note are still insufficient to fund operations for the next twelve months, and the filing notes substantial doubt about the company’s ability to continue as a going concern.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported third‑quarter results with no revenue and a net loss of $2.35 million. For the nine months ended September 30, 2025, the company recorded a net loss of $9.11 million. Operating expenses were $2.27 million in the quarter, led by research and development of $0.94 million and general and administrative of $0.89 million.
Cash and cash equivalents were $2.09 million at quarter‑end. Total assets were $3.54 million, liabilities $2.15 million, and stockholders’ equity $1.39 million. The company executed multiple financings in 2025, including $5.0 million net proceeds from a March public offering and $3.9 million net from a June private placement with pre‑funded warrants; a $2.0 million revolving note remained undrawn. On November 3, 2025, SHPH closed a private placement of a pre‑funded warrant for gross $2.5 million. Management disclosed substantial doubt about continuing as a going concern. The company also signed a binding term sheet on October 20, 2025 to acquire Molecule’s assets and liabilities for $10,000,000 in cash and stock, subject to definitive agreements and approvals.
Shuttle Pharmaceuticals (SHPH) reported continued development-stage operations with no revenue and a six-month net loss of $6,759,472. Cash and cash equivalents rose to $4,817,672 at June 30, 2025 from $1,920,144 at year-end 2024, driven by net financing proceeds of approximately $8.78 million. Total assets were $5.50 million and stockholders' equity increased to $3.61 million as shares outstanding expanded to 1,070,773.
The company disclosed a substantial doubt about its ability to continue as a going concern: management states existing cash, equity proceeds and an undrawn $2.0 million revolving note are not expected to fund operations and clinical trials through the next 12 months. Material items include reverse stock splits to meet Nasdaq requirements, equity financings in March and June 2025, accelerated stock-based compensation of about $0.5 million from RSU modifications, and a $2.0 million payment to an IR agency recorded as expense.